|
Z.R. Shodmonova, R.R. Gafarov, S.A. Allazov, Sh.I. Giyasov
Phosphodesterase type 5 inhibitors – clinical efficiency and role in therapy for erectile dysfunction
|
№2 / 2021
|
|
A.A. Kaputovskij
Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction
|
№6 / 2019
|
|
A.A. Kamalov, A.N. Nizov
Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction
|
№4 / 2019
|
|
I.L. Nikitina, G.G. Gaysina, Sh.N. Galimov, K.V. Bulygin, E.F. Galimova, V.N. Pavlov
Safety of tadalafil in patients with cardiovascular comorbidities
|
№1 / 2019
|
|
D.V. Ergakov, A.G. Martov
The Modern View of Conservative Therapy of Lower Urinary Tract Symptoms in Men
|
№5 / 2015
|
|
P.I. Motin, M.I. Andrjuhin, S.A. Pul'bere, O.Ju. Alekseev, N.K. Agaev
Treatment of erectile dysfunction following transvesical prostatectomy
|
№4 / 2015
|
|
E. A. Efremov, E. V. Kasatonova, Ja. I. Mel'nik
Use of sildenafil citrate for treatment of erec-tile dysfunction of various etiology
|
№2 / 2015
|
|
S.O. Yudovsky, D.Yu. Pushkar
Correction of erectile dysfunction in patients undergoing radical prostatec- tomy
|
№2 / 2014
|
|
A.A. Tomilov, E.N. Golubtsova
Combined treatment of patients with lower urinary tract symptoms and erectile dysfunction
|
№5 / 2013
|
|
Gamidov S.I., Iremashvili V.V., Popova A.Yu.
Modernity in the treatment of erectile dysfunction: Levitra (vardenafil) in the form of soluble oral tablet
|
№3 / 2013
|
|
Kamalov A.A., Osmolovsky B.E., Okhobotov D.A., Khodyreva L.A., Takhirzade T.B., Tahirzade A.M., Gevorkyan A.R.
Combined treatment of patients with erectile dysfunction and disorders of urination
|
№3 / 2013
|
Русский
